Reuters logo
2 months ago
BRIEF-Regeneron details royalty agreement with Novartis for canakinumab
June 22, 2017 / 1:08 PM / 2 months ago

BRIEF-Regeneron details royalty agreement with Novartis for canakinumab

June 22 (Reuters) - Regeneron Pharmaceuticals Inc

* Regeneron details royalty agreement with novartis for canakinumab (acz885)

* Regeneron pharmaceuticals inc - provided details of royalty it receives on any sales of canakinumab (acz885), an anti-il1β antibody

* Regeneron pharmaceuticals inc - has not reviewed cantos data and cannot predict whether study will result in new indications or sales in future

* Regeneron pharmaceuticals inc - regeneron is not involved in development and regulatory process for canakinumab Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below